Matches in SemOpenAlex for { <https://semopenalex.org/work/W2598494085> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2598494085 abstract "8539 Background: Ipilimumab (ipi) is a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 to augment antitumor immune responses. In a phase III trial, ipi at 10 mg/kg plus dacarbazine (DTIC) improved overall survival in previously untreated patients (pts) with MM. In ipi studies, the most common drug-related adverse events (AEs) were immune-related, which were generally reversible using treatment guidelines involving prompt recognition, intervention (corticosteroids, and rarely, alternative immunosuppressive agents), and possible discontinuation of therapy. The purpose of this analysis is to evaluate outcomes of ipi treatment-related AEs with use of systemic corticosteroids. Methods: AEs were reported from the first ipi dose up to 70 days after the last dose. Immune-mediated adverse reactions (imARs) were used to characterize inflammatory AEs in previously untreated pts with MM who received ipi plus DTIC in a phase III trial. This analysis includes the imAR categories of hepatitis, dermatitis, enterocolitis, and endocrinopathies. Results: More than 70% of pts who received corticosteroids had complete resolution of the imAR, ie, last reported Grade (Gr) of 0 (Table). In pts for whom a high-grade imAR had not completely resolved at the last report, ≥50% had improved to Gr 1. Conclusions: In the majority of pts treated with ipi at 10 mg/kg plus DTIC who received corticosteroids for the management of imARs, as recommended per treatment guidelines, the most common imARs had completely resolved or improved to Gr 1. [Table: see text]" @default.
- W2598494085 created "2017-04-07" @default.
- W2598494085 creator A5015975033 @default.
- W2598494085 creator A5028034211 @default.
- W2598494085 creator A5029398339 @default.
- W2598494085 creator A5031603638 @default.
- W2598494085 creator A5032777196 @default.
- W2598494085 creator A5033937088 @default.
- W2598494085 creator A5050974773 @default.
- W2598494085 creator A5054656505 @default.
- W2598494085 creator A5070581787 @default.
- W2598494085 creator A5071046741 @default.
- W2598494085 date "2012-05-20" @default.
- W2598494085 modified "2023-09-22" @default.
- W2598494085 title "Outcomes of ipilimumab treatment-related adverse events in patients with metastatic melanoma (MM) who received systemic corticosteroids in a phase III trial." @default.
- W2598494085 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.8539" @default.
- W2598494085 hasPublicationYear "2012" @default.
- W2598494085 type Work @default.
- W2598494085 sameAs 2598494085 @default.
- W2598494085 citedByCount "5" @default.
- W2598494085 countsByYear W25984940852013 @default.
- W2598494085 countsByYear W25984940852014 @default.
- W2598494085 countsByYear W25984940852015 @default.
- W2598494085 countsByYear W25984940852017 @default.
- W2598494085 countsByYear W25984940852019 @default.
- W2598494085 crossrefType "journal-article" @default.
- W2598494085 hasAuthorship W2598494085A5015975033 @default.
- W2598494085 hasAuthorship W2598494085A5028034211 @default.
- W2598494085 hasAuthorship W2598494085A5029398339 @default.
- W2598494085 hasAuthorship W2598494085A5031603638 @default.
- W2598494085 hasAuthorship W2598494085A5032777196 @default.
- W2598494085 hasAuthorship W2598494085A5033937088 @default.
- W2598494085 hasAuthorship W2598494085A5050974773 @default.
- W2598494085 hasAuthorship W2598494085A5054656505 @default.
- W2598494085 hasAuthorship W2598494085A5070581787 @default.
- W2598494085 hasAuthorship W2598494085A5071046741 @default.
- W2598494085 hasConcept C121608353 @default.
- W2598494085 hasConcept C126322002 @default.
- W2598494085 hasConcept C143998085 @default.
- W2598494085 hasConcept C16005928 @default.
- W2598494085 hasConcept C185926286 @default.
- W2598494085 hasConcept C197934379 @default.
- W2598494085 hasConcept C2777658100 @default.
- W2598494085 hasConcept C2777701055 @default.
- W2598494085 hasConcept C2781433595 @default.
- W2598494085 hasConcept C2994587330 @default.
- W2598494085 hasConcept C502942594 @default.
- W2598494085 hasConcept C530470458 @default.
- W2598494085 hasConcept C71924100 @default.
- W2598494085 hasConceptScore W2598494085C121608353 @default.
- W2598494085 hasConceptScore W2598494085C126322002 @default.
- W2598494085 hasConceptScore W2598494085C143998085 @default.
- W2598494085 hasConceptScore W2598494085C16005928 @default.
- W2598494085 hasConceptScore W2598494085C185926286 @default.
- W2598494085 hasConceptScore W2598494085C197934379 @default.
- W2598494085 hasConceptScore W2598494085C2777658100 @default.
- W2598494085 hasConceptScore W2598494085C2777701055 @default.
- W2598494085 hasConceptScore W2598494085C2781433595 @default.
- W2598494085 hasConceptScore W2598494085C2994587330 @default.
- W2598494085 hasConceptScore W2598494085C502942594 @default.
- W2598494085 hasConceptScore W2598494085C530470458 @default.
- W2598494085 hasConceptScore W2598494085C71924100 @default.
- W2598494085 hasLocation W25984940851 @default.
- W2598494085 hasOpenAccess W2598494085 @default.
- W2598494085 hasPrimaryLocation W25984940851 @default.
- W2598494085 hasRelatedWork W1802023319 @default.
- W2598494085 hasRelatedWork W2095267413 @default.
- W2598494085 hasRelatedWork W2095826876 @default.
- W2598494085 hasRelatedWork W2097995306 @default.
- W2598494085 hasRelatedWork W2112403746 @default.
- W2598494085 hasRelatedWork W2123536758 @default.
- W2598494085 hasRelatedWork W2243558653 @default.
- W2598494085 hasRelatedWork W2247589483 @default.
- W2598494085 hasRelatedWork W2254875398 @default.
- W2598494085 hasRelatedWork W2267367070 @default.
- W2598494085 hasRelatedWork W2276033320 @default.
- W2598494085 hasRelatedWork W2463257517 @default.
- W2598494085 hasRelatedWork W2475687906 @default.
- W2598494085 hasRelatedWork W2556120223 @default.
- W2598494085 hasRelatedWork W2596647083 @default.
- W2598494085 hasRelatedWork W2615736024 @default.
- W2598494085 hasRelatedWork W2624791371 @default.
- W2598494085 hasRelatedWork W2760563623 @default.
- W2598494085 hasRelatedWork W2797778196 @default.
- W2598494085 hasRelatedWork W3004870356 @default.
- W2598494085 isParatext "false" @default.
- W2598494085 isRetracted "false" @default.
- W2598494085 magId "2598494085" @default.
- W2598494085 workType "article" @default.